LBA2 A window-of-opportunity (WOO) trial of giredestrant +/- LHRH analogue vs anastrozole + LHRHa in premenopausal patients with ER+/HER2- early breast cancer: PREcoopERA

ESMO Open 2026 Open access

Read full text
Authors: E. Munzone, R. Shi, V. Bjelic-Radisic, A. Perello Martorell, R.M. Connolly, J. M. Ribeiro, F. Conforti, M. Sirico, A. Gonzalez-Haba Martinez, E. Felip Falgas, V.L. Obadia Gil, B. Rojas Garcia
+8 more S. Morales, D. Langanke, R. Kammler, P. Dell’Orto, L. Russo, M.A. Colleoni, S. Loi, P. Dubsky
DOI: 10.1016/j.esmoop.2026.107277
Cited by: 1

Abstract

The pharmacodynamic mechanisms of oral SERDs, competition for E2 binding and ER degradation, may retain activity in the presence of higher E2 levels of premenopausal pts with ER+ early BC differently from aromatase inhibitor. The SERD giredestrant (G) showed improved anti-proliferative activity vs anastrozole (A) in postmenopausal pts (coopERA trial), and superior iDFS in the Phase III lidERA trial, which required G+LHRH for premenopausal pts. We investigated the anti-proliferative activity of G +/- LHRH.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies Breast Cancer Treatment Studies

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
107277–107277
Publication date
1 May 2026
Language
EN